Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors
Aaron Smith, Cynthia M. Shafer(Novartis (Switzerland)), Laura Tandeske, Takanori Kanazawa, Hanne Merritt, Daniel Poon(Rapt Therapeutics (United States)), Jeremy Murray(Novartis (Switzerland)), Darrin D. Stuart(Proteostasis Therapeutics (United States)), Sandra W. Cowan‐Jacob(Novartis (Switzerland)), Johanna M. Jansen, B.A. Appleton(Novartis (Switzerland)), Kevin Shoemaker, John S.D. Chan(Centre Hospitalier de l’Université de Montréal), Zheng Chen(Beijing Tian Tan Hospital), Qiong Zhang(Huazhong University of Science and Technology), Zilin Huang, Susan Kaufman(Genesys (United States)), Clemens Scheufler(Novartis (Switzerland)), Zhi‐Jie Ni, Kay Huh
Cited by 8
Related Papers
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Attitudes and perceptions of UK medical students towards artificial intelligence and radiology: a multicentre survey
|Insights into Imaging|2020|492
Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity
|ChemMedChem|2019|193
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
|Journal of Medicinal Chemistry|2021|168
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae
|Cell Metabolism|2019|132